Esperion Therapeutics, Inc.

NasdaqGM ESPR

Esperion Therapeutics, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD 1.78

Esperion Therapeutics, Inc. Revenue Per Share is USD 1.78 for the Trailing 12 Months (TTM) ending September 30, 2024, a 60.97% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • Esperion Therapeutics, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 1.10, a -12.40% change year over year.
  • Esperion Therapeutics, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 1.26, a -54.27% change year over year.
  • Esperion Therapeutics, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 2.75, a -65.27% change year over year.
  • Esperion Therapeutics, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 7.93, a -35.58% change year over year.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
NasdaqGM: ESPR

Esperion Therapeutics, Inc.

CEO Mr. Sheldon L. Koenig
IPO Date June 26, 2013
Location United States
Headquarters 3891 Ranchero Drive
Employees 240
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Similar companies

ITCI

Intra-Cellular Therapies, Inc.

USD 126.89

-0.24%

SIGA

SIGA Technologies, Inc.

USD 6.33

4.46%

AVDL

Avadel Pharmaceuticals plc

USD 8.05

2.94%

IRWD

Ironwood Pharmaceuticals, Inc.

USD 3.65

-3.18%

LFCR

Lifecore Biomedical, Inc.

USD 6.43

1.10%

NBIX

Neurocrine Biosciences, Inc.

USD 139.51

-2.46%

ALKS

Alkermes plc

USD 28.50

0.53%

PCRX

Pacira BioSciences, Inc.

USD 20.55

-2.74%

PBH

Prestige Consumer Healthcare Inc.

USD 75.78

1.54%

PAHC

Phibro Animal Health Corporation

USD 20.28

0.05%

ANIP

ANI Pharmaceuticals, Inc.

USD 54.16

0.43%

ELAN

Elanco Animal Health Incorporated

USD 11.70

0.00%

COLL

Collegium Pharmaceutical, Inc.

USD 33.18

-1.80%

RMTI

Rockwell Medical, Inc.

USD 2.00

-0.50%

StockViz Staff

January 15, 2025

Any question? Send us an email